Wall Street Just Sent a Clear Signal on GTLB — Nine Analysts Cut Price Targets After FY27 Guidance Disappoints

Core Viewpoint - GitLab's strong Q4 earnings were overshadowed by disappointing FY27 guidance, leading to widespread price target cuts from analysts [2][4][6]. Financial Performance - GitLab reported Q4 revenue of $260.40 million, representing a 23.2% year-over-year increase, exceeding estimates by approximately $8 million [3][6]. - Non-GAAP EPS for Q4 was $0.30, surpassing the consensus estimate of $0.23 by 30% [3][6]. - The company achieved over $1 billion in total Annual Recurring Revenue (ARR) and had 155 customers with over $1 million in ARR, a 26% increase year-over-year [3]. Guidance Issues - FY27 non-GAAP EPS guidance was set at $0.76-$0.80, a significant decline from the $0.96 delivered in FY26 [4][6]. - FY27 revenue guidance of $1.099 billion to $1.118 billion indicates a growth rate below the consensus expectation of 15-17% [4][6]. Analyst Reactions - Nine analysts cut their price targets following the guidance announcement, indicating a coordinated re-rating across the board [5][6]. - Barclays reduced its target to $25 from $29, maintaining an Underweight rating [7]. - JPMorgan lowered its target to $28 from $53, keeping a Neutral rating while acknowledging the $1 billion ARR milestone [7]. - Piper Sandler downgraded to Neutral from Overweight, cutting its target to $28 from $55 [7]. - Wells Fargo reduced its target to $26 from $45, framing FY27 as a year of stabilization [7]. - BTIG cut its target to $30 from $32, maintaining a Buy rating but noting that FY27 growth guidance was below consensus [7]. - Canaccord's Kingsley Crane lowered its target to $40 from $70, keeping a Buy rating and highlighting the highest net new ARR in company history [7]. - BofA cut its target to $58 from $72, maintaining a Buy rating and describing the results as mixed [7]. - Bernstein lowered its target to $60 from $70, keeping an Outperform rating, but noted this was the fourth consecutive quarter of guidance below consensus [7]. - UBS cut its target to $44 from $51, maintaining a Buy rating [7].